Business
BBOT Appoints Industry Veteran Uneek Mehra as Chief Financial Officer
SOUTH SAN FRANCISCO, Calif., July 21, 2025--TheRas, Inc. d/b/a BBOT, a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced the appointment of Uneek Mehra as Chief Financial Officer. Mr. Mehra brings more than 28 years of global financial and business leadership experience across the biotechnology and pharmaceutical industries.
About this update from 4d Molecular Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/5c2c918786800c21223d78ce273edc8a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/zK9LbF3UY4Ercf7ReyhiFw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/5c2c918786800c21223d78ce273edc8a","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/HKRVActnRfiTT94ApoJ_SA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/5c2c918786800c21223d78ce273edc8a","width":1024,"height":512}},"lazy":false},{"type":"text","content":"Seasoned financial executive brings decades of strategic leadership and financial acumen across biotech and global healthcare to BBOT’s executive team","length":150,"tagName":"p","attribs":{}},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., July 21, 2025--(BUSINESS WIRE)--TheRas, Inc. d/b/a BBOT, a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced the appointment of Uneek Mehra as Chief Financial Officer. Mr. Mehra brings more than 28 years of global financial and business leadership experience across the biotechnology and pharmaceutical industries.","length":387,"tagName":"p"},{"type":"text","content":""We are thrilled to welcome Uneek to BBOT," said Eli Wallace, PhD, Chief Executive Officer of BBOT. "His proven track record of driving financial strategy, building high-impact partnerships, and supporting the growth of innovative biotech companies will be instrumental as we continue to advance our promising oncology pipeline, and scale our operations."","length":375,"tagName":"p"},{"type":"text","content":"Mr. Mehra most recently served as Chief Financial & Business Officer at 4D Molecular Therapeutics (4DMT) where he led a successful $325M financing as well as capital allocation efforts to ensure funding for two large Phase 3 programs. Prior to that, he was the Chief Financial and Business Officer at Myovant Sciences Ltd., a public biopharma company, where he successfully built partnerships, and enabled significant commercial growth for its Oncology and Women’s Health products. He also led Myovant Sciences’ acquisition by Su...